Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial
Year: 2014
Type: article
Source: The Lancet Oncology
Institutions: Université Paris-Sud, Institut Gustave Roussy, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, Charité – Universitätsmedizin Berlin, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Azienda Ospedaliera San Camillo-Forlanini, Northwestern University, Medivation, Inc. (United States), Institute of Cancer Research, Royal Marsden Hospital
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Astellas Pharma
OpenAlex ID: W2131952914